‹ ›
MYP_134346
← PREVIOUS NEXT → BACK
Basic Information
IBP20
Anticancer ▸ Cytotoxic anticancer activity ▸ Cytotoxic
Antimicrobial
Antiviral
Antiviral ▸ Anti-Coronavirus ▸ Anti-SARS-CoV
Antiviral ▸ Anti-Coronavirus ▸ Anti-SARS-CoV-2
Antiviral ▸ Antiviral mechanism ▸ Viral fusion inhibition
Membrane / Ion-channel modulation ▸ Sodium channel modulation ▸ Sodium channel inhibitor
Membrane / Ion-channel modulation ▸ Sodium channel modulation ▸ Sodium channel inhibitor cross
Toxicity / Safety ▸ Cytotoxicity ▸ Cytotoxic
Venom / Toxin ▸ General toxin ▸ Cytotoxic
Standard
37 amino acids
C192H317N51O63
Standard
Sequence
SVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIK
Physicochemical Analysis
4347.87 Da
4.77
-2.53
-2.76
-0.0684
-0.60
0.70
-0.12
40.54
121.08
0.0541
2980.00
2980.00
The radar chart summarizes major physicochemical dimensions for quick comparison, while exact numerical values remain listed on the left.
Residue Composition
Amino Acid Composition
Chemical Descriptors
1920.55
-16.88
63.0
61.0
156.0
306.0
2.0
43.0
Structural Visualization
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber in the current view mode. Use the buttons to zoom.
2D CHEMICAL STRUCTURE
Drag to move
Drag to move. Use the buttons to zoom.
Experimental Records
RECORD: Rec_0229652 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
HR2 fusion-inhibitory peptide
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
Toc(tocophenol)
Toc(tocophenol)
Bio-Activity Profile
Antiviral Anti-SARS-CoV-2 Fusion inhibition
SARS-CoV-2 | protein-mediated cell; -cell
0.03907 μM
IC50
Mammalian: 1.9 h; Yeast: >20 h; E. coli: >10 h
PaperStructure-based design and characterization of novel fusion-inhibitory lipopeptides against SARS-CoV-2 and emerging variants. | Yu D, Zhu Y, Jiao T, Wu T, Xiao X, Qin B, Chong H, Lei X, Ren L, Cui S, Wang J, He Y. | Emerg Microbes Infect. 2021 Dec;10(1):1227-1240. | DOI:10.1080/22221751.2021.1937329 | PMID:34057039 PMID34057039 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/34057039/
RECORD: Rec_0230479 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
PEG5-K(Chol)
Bio-Activity Profile
Antimicrobial Anti-SARS-CoV-2
Virus
PaperStructure-based design and characterization of novel fusion-inhibitory lipopeptides against SARS-CoV-2 and emerging variants PMID34057039 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/34057039/
RECORD: Rec_0233981 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
HR2 fusion-inhibitory peptide
32630
Structure & Mods
linear peptide [Linear]
noncanonical stereochemical modification [Modified]
None
PEG8-K(Chol)
PEG8-K(Chol)
Bio-Activity Profile
Antiviral Anti-SARS-CoV-2 Fusion inhibition
SARS-CoV-2 B.1.1.7 | Huh-7 cells
0.00718 μM
IC50
Mammalian: 1.9 h; Yeast: >20 h; E. coli: >10 h
PaperStructure-based design and characterization of novel fusion-inhibitory lipopeptides against SARS-CoV-2 and emerging variants. | Yu D, Zhu Y, Jiao T, Wu T, Xiao X, Qin B, Chong H, Lei X, Ren L, Cui S, Wang J, He Y. | Emerg Microbes Infect. 2021 Dec;10(1):1227-1240. | DOI:10.1080/22221751.2021.1937329 | PMID:34057039 PMID34057039 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/34057039/
RECORD: Rec_0235046 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
PEG4-K(Chol)
Bio-Activity Profile
Antimicrobial Anti-SARS-CoV-2
SARS-CoV-2:inhibition of SARS-CoV-2 S protein-mediated cell-cell fusion
0.00033 μM
IC50
PaperStructure-based design and characterization of novel fusion-inhibitory lipopeptides against SARS-CoV-2 and emerging variants PMID34057039 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/34057039/
RECORD: Rec_0235855 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
HR2 fusion-inhibitory peptide
32630
Structure & Mods
linear peptide [Linear]
noncanonical stereochemical modification [Modified]
None
PEG4-K(Chol)
PEG4-K(Chol)
Bio-Activity Profile
Antiviral Anti-SARS-CoV-2 Fusion inhibition
SARS-CoV-2 | protein-mediated cell; -cell
0.00033 μM
IC50
Mammalian: 1.9 h; Yeast: >20 h; E. coli: >10 h
PaperStructure-based design and characterization of novel fusion-inhibitory lipopeptides against SARS-CoV-2 and emerging variants. | Yu D, Zhu Y, Jiao T, Wu T, Xiao X, Qin B, Chong H, Lei X, Ren L, Cui S, Wang J, He Y. | Emerg Microbes Infect. 2021 Dec;10(1):1227-1240. | DOI:10.1080/22221751.2021.1937329 | PMID:34057039 PMID34057039 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/34057039/
FIRST PREV 1 ... 16 17 18 19 20 ... 31 NEXT LAST
Showing 5 records on this page · Page 18 of 31